Advanced commercialization in the US, signing multiple new customer and distribution agreements for Nanox.ARC and accelerated activities around Nanox.AI
Management to host conference call and webcast
Appointed new CFO effective
PETAH TIKVA,
Recent Highlights:
- Generated
$3.7 million in revenue in the fourth quarter of 2025, compared to$3.0 million in the fourth quarter of 2024. - Completed the acquisition of 100% of the stock of
Vaso Healthcare IT Corp. (nowNanox Health IT Inc. , “Nanox Health IT”), a provider of healthcare information technologies solutions, for cash and future operational based earnouts. - Entered into a distribution agreement with Howard Technology Solutions (“Howard”), a division of
Howard Industries to deploy 300 Nanox.ARC systems across theU.S. over three years. - Initiated a restructuring of semiconductor manufacturing operations at Nanox’ South Korean facility to reduce operating expenses and enhance manufacturing efficiencies, while also taking steps to secure the Company’s supply chain.
- Continued to advance the deployment of the Nanox.ARC systems through direct sales and commercial collaborations, with approximately 36 systems in various stages of deployment, additional 17 systems expected to be installed over the following months as part of the Nanox Imaging Network initiative, and executed distribution agreements (including Howard) for approximately 360 Capex systems in the
U.S. over the next two to three years, with timing dependent on regulatory, operational, and market factors. - Advanced clinical and regulatory work which supports commercial efforts, including adding Cedars Sinai in
Los Angeles as a clinical trial partner evaluating the Nanox.AI aortic valve calcification solution. - On
April 14, 2026 , the Company appointedGuy Nathanzon as Chief Financial Officer, effectiveAugust 1, 2026 .Mr. Nathanzon brings extensive financial leadership experience inU.S. publicly traded companies, including senior executive roles as Chief Financial Officer and Chief Operating Officer. His experience includes capital markets, mergers and acquisitions, capital raises and global financial operations.Mr. Nathanzon also has experience in the medical technology sector, having previously served as Chief Financial Officer ofScopio Labs and most recently as Chief Financial Officer of Valens Semiconductor, a company listed on theNew York Stock Exchange .
The Company’s Chief Financial Officer,Ran Daniel , decided to step down from his position, effectiveJuly 31, 2026 , after five years with the Company.Mr. Daniel will remain with the Company for a transition period to ensure an orderly handover of responsibilities.Mr. Nathanzon is expected to join the Company onJuly 14, 2026 , to facilitate the transition. The Company expects to maintain continuity in its financial operations and reporting throughout the transition period. Mr. Daniel’s departure to pursue new endeavors is not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices.
- The Company is closely monitoring the evolving geopolitical situation in the
Middle East . As of the date of this report, the Company has not experienced any material disruption to its operations as a result of the current geopolitical developments, and its business continues to operate as planned across its global operations. However, the situation remains dynamic, and the Company will continue to monitor developments closely. There can be no assurance that the ongoing geopolitical developments will not have an impact on the Company’s operations, financial condition, or results of operations in the future.
“The fourth quarter of 2025 was marked by strong momentum across all Nanox business segments, particularly good commercial progress in theU.S. market,” saidErez Meltzer , Nanox Chief Executive Officer and acting Chairman of the Board of Directors.
“Our top priority remains accelerating the deployment of our flagship Nanox.ARC system through a combination of our direct sales team and a growing lineup of distribution collaborations with established medical imaging providers. We are focused on Capex collaborations with distribution partners and recently executed agreements for distribution of approximately 360 Nanox.ARC systems in the coming two to three years, which represents a shift in how we are scaling our business.
In parallel, we have nearly completed the integration of Nanox Health IT and have secured manufacturing capabilities to meet anticipated demand. We have also initiated a restructuring of our Korean facility to strengthen our financial footing.
We believe the foundation we have in place positions Nanox to achieve the commercial goals we have set for this year and beyond.”
Financial results for three months ended December 31, 2025
For the three months ended
The Company reported revenue of
The Company’s gross loss during the reported period totaled
The Company’s revenue from teleradiology services for the reported period was
During the reported period, the Company generated revenue through the sales and deployment of its imaging systems which amounted to
The Company’s revenue from its AI and Software solutions for the reported period was
Research and development expenses, net, for the reported period were
Sales and marketing expenses for the reported period were
General and administrative expenses for the reported period were
Other expenses, net for the reported period, were
Recently the Company adopted a restructuring plan intended to better align its manufacturing cost structure with its long-term financial model, support its path toward improved gross margins, and align its manufacturing capabilities with current and anticipated business needs and the Company’s strategic priorities.
As part of this plan and the Company’s broader cost reduction efforts, the Company is restructuring its manufacturing footprint to improve gross margins, reduce capital expenditures, and enhance operational efficiency. This includes transitioning away from certain manufacturing activities at its facility in
In connection with this transition, the Company expects to utilize its existing emitter inventory as it shifts to a more efficient outsourced production model that is better aligned with current and anticipated demand.
As part of the restructuring, the Company will close its chip manufacturing line in
In connection with the restructuring, the Company expects to incur total restructuring and related charges of approximately
Accordingly, the Company recorded a non-cash impairment charge of approximately
The Company continues to evaluate the overall composition of the restructuring-related charges, including potential additional cash components. The remaining restructuring-related costs, if any, are expected to be incurred over the course of the implementation of the restructuring plan.
The estimates of the total charges and the timing thereof are subject to a number of assumptions and uncertainties, and actual results may differ materially.
Non-GAAP net loss attributable to ordinary shares for the reported period was
Non-GAAP gross loss for the reported period was
The difference between the GAAP and non-GAAP financial measures above is mainly attributable to amortization of intangible assets, share-based compensation, change in contingent earnout liability, expenses related to an offering and legal fees, expenses in connection with the settlement with a shareholder and an Impairment of long-lived assets. A reconciliation between GAAP and non-GAAP financial measures for the three- and twelve-month periods ended
Update on Systems Deployment
The Company has continued to make progress in advancing its deployment activities; however, the pace of deployment remains subject to a number of factors, some of which are outside the Company’s control, including import licensing requirements, construction timelines, and regulatory processes in certain markets. These factors have and may in the future continue to impact the timing of system installations and activation.
The Company expects that, over time, certain of these processes may become more streamlined as additional sites advance through the deployment pipeline; however, there can be no assurance as to the timing or extent of such improvements.
To date, the Company has approximately 36 systems in various stages of deployment, including clinical, demonstrations, commercial installations, and systems pending construction and/or regulatory approvals. Most of the deployed systems have not yet begun to generate revenues. Furthermore, approximately 17 systems are expected to be installed over the following months under the Nanox Imaging Network (“NIN”), a limited Proof-of-Concept (“POC”) initiative, in collaboration with
In addition, as part of the commercial shift in focus, the Company has recently entered into distribution agreements for approximately 360 Capex systems in
Such anticipated volumes, if executed as expected, reflect the Company’s current commercial arrangements and the expected activities of its distribution partners; however, the timing and extent of actual purchases are subject to a number of factors, including market adoption, customer demand, site readiness, construction timelines, regulatory approvals, and the performance of such partners.
While these agreements represent expected commercial activity over time, many have not yet resulted in revenue, and the timing and extent of revenue recognition will depend on the progression of deployments, system activations, and other factors, including the performance of the Company’s distribution partners.
The introduction of new medical technologies typically involves complex and multi-stage processes, including integration into clinical workflows, compliance with regulatory frameworks, and development of supporting operational infrastructure. These factors may extend deployment timelines, particularly in early stages, and may impact the timing of revenue generation.
2026 Full-Year Guidance
The guidance that follows supersedes all prior financial guidance or outlook statements made by the Company, constitutes forward-looking information within the meaning of applicable securities laws, and is based on a number of assumptions and subject to a number of risks. Actual results could vary materially as a result of numerous factors, including certain known and unknown uncertainties and risk factors, many of which are beyond the Company’s control. Please see “Forward-Looking Statements” below for more information.
The Company continues to target
However, the Company’s current revenue base remains at an early stage, and the timing and pace of revenue growth are expected to depend primarily on the timing of system activations, the transition of installed systems into revenue-generating operations, and the impact of deployments carried out by the Company’s business partners.
As additional systems become operational and utilization increases, the Company expects revenue to grow over time. However, the timing and magnitude of such growth may vary and are subject to a number of factors, including deployment progress, regulatory approvals, and other factors beyond the Company’s control.
Liquidity and Capital Resources
As of
We expect that we will need to obtain additional financing to implement our business plan such as the financing we consummated with a single institutional investor in November of 2025 and the utilization of our Controlled Equity OfferingSM Sales Agreement. Any inability to raise adequate funds on commercially reasonable terms could have a material adverse effect on our business, financial condition, results of operation and prospects.
Other Assets
As of
As of
Shareholders’ Equity
As of
Conference Call and Webcast Details
Individuals interested in listening to the conference call may do so by joining the live webcast on the Investors section of the Nanox website under Events and Presentations. Alternatively, individuals can register online to receive a dial-in number and personalized PIN to participate in the call. An archived webcast of the event will be available for replay following the event.
About Nanox:
Nanox (NASDAQ: NNOX) is focused on driving the world’s transition to preventive health care by delivering an integrated, end-to-end medical imaging and healthcare services platform.
Nanox combines affordable imaging hardware, advanced AI-based solutions, cloud-based software, access to remote radiology, health IT solutions, and a marketplace to enable earlier detection, improved clinical efficiency, and broader access to care.
Nanox’s vision is to expand the reach of medical imaging both within and beyond traditional hospital settings by providing a seamless solution from scan to interpretation and beyond. By leveraging proprietary digital X-ray technology, AI-driven analytics, and a clinically driven approach, Nanox aims to enhance the efficiency of routine imaging workflows, support early detection of disease, and improve patient outcomes.
The Nanox ecosystem includes Nanox.ARC, a cost-effective, 3D multi-source digital tomosynthesis imaging system designed for ease of use and scalability; Nanox.AI, a suite of AI-based algorithms that augment the interpretation of routine CT imaging to identify early signs often associated with chronic disease; Nanox.CLOUD, a cloud-based platform for secure data management, storage, and advanced imaging analytics; Nanox.MARKETPLACE and
By integrating imaging technology, AI, cloud infrastructure, clinical expertise, a marketplace, and health information technology, Nanox seeks to lower barriers to adoption, improve utilization, and advance preventive care worldwide. For more information, please visit https://www.nanox.vision.
Forward-Looking Statements
This press release may contain forward-looking statements and forward-looking information (collectively, the “forward-looking statements”), that are subject to risks and uncertainties. All statements that are not historical facts contained in this press release are forward-looking statements. Such statements include, but are not limited to, any statements relating to: the Company’s full-year revenue target and the assumptions underlying such guidance; guidance with respect to the number of units that the Company expects to have deployed by the end of the 2025 year the Company’s financial outlook, including expected revenue for the fiscal year; the Company’s expectation that its revenue base will grow as additional systems become operational and utilization increases, and the timing and pace of such growth; the expected timing and progression of system activations, installations, and the transition of installed systems into revenue-generating operations; the ability to successfully integrate Nanox Health IT following the acquisition as well as to improve deployment speed, pace and implementation quality; the initiation, timing, progress and results of the Company’s research and development, manufacturing, and commercialization activities with respect to its X-ray source technology and the Nanox.ARC; the Company’s clinical and regulatory initiatives; the ability of the Company to realize the expected benefits of its recent acquisitions and the projected business prospects of the Company and the acquired companies; the Company’s restructuring plan, including the expected closure of the chip manufacturing line in
For a discussion of other risks and uncertainties, and other important factors, any of which could cause Nanox’s actual results to differ from those contained in the Forward-Looking Statements, see the section titled “Risk Factors” in Nanox’s Annual Report on Form 20-F for the year ended
Non-GAAP Financial Measures
This press release includes information about certain financial measures that are not prepared in accordance with generally accepted accounting principles in
CONSOLIDATED BALANCE SHEETS ( |
||||||
2025 |
2024 |
|||||
| Assets | ||||||
| CURRENT ASSETS: | ||||||
| Cash and cash equivalents | 49,151 | 39,304 | ||||
| Short-term deposits | 10,459 | 15,500 | ||||
| Marketable securities | - | 18,402 | ||||
| Accounts receivables net of allowance for credit losses of |
2,013 | 1,805 | ||||
| Inventories | 3,070 | 1,493 | ||||
| Prepaid expenses | 1,255 | 827 | ||||
| Other current assets | 845 | 1,349 | ||||
| TOTAL CURRENT ASSETS | 66,793 | 78,680 | ||||
| NON-CURRENT ASSETS: | ||||||
| Restricted deposit | 361 | 337 | ||||
| Long-term deposits | - | 10,000 | ||||
| Property and equipment, net | 29,677 | 45,355 | ||||
| 316 | - | |||||
| Operating lease right-of-use asset | 3,518 | 3,843 | ||||
| Intangible assets | 59,868 | 69,995 | ||||
| Other non-current assets | 1,632 | 1,792 | ||||
| TOTAL NON-CURRENT ASSETS | 95,372 | 131,322 | ||||
| TOTAL ASSETS | 162,165 | 210,002 | ||||
| Liabilities and Shareholders’ Equity | ||||||
| CURRENT LIABILITIES: | ||||||
| Short-term loan | 3,136 | 3,061 | ||||
| Accounts payable | 2,886 | 2,209 | ||||
| Accrued expenses | 4,224 | 3,968 | ||||
| Deferred revenue | 534 | 140 | ||||
| Contingent short-term earnout liability | 304 | - | ||||
| Current maturities of operating lease liabilities | 950 | 745 | ||||
| Other current liabilities | 4,854 | 3,849 | ||||
| TOTAL CURRENT LIABILITIES | 16,888 | 13,972 | ||||
| NON-CURRENT LIABILITIES: | ||||||
| Non-current operating lease liabilities | 3,765 | 3,640 | ||||
| Non-current deferred revenue | 17 | - | ||||
| Contingent long-term earnout liability | 173 | - | ||||
| Deferred tax liability | 600 | 2,576 | ||||
| Other long-term liabilities | 990 | 695 | ||||
| TOTAL NON-CURRENT LIABILITIES | 5,545 | 6,911 | ||||
| TOTAL LIABILITIES | 22,433 | 20,883 | ||||
| COMMITMENTS AND CONTINGENCIES (Note 3) | ||||||
| SHAREHOLDERS’ EQUITY: | ||||||
| Ordinary Shares, par value |
198 | 181 | ||||
| Additional paid-in capital | 588,301 | 562,688 | ||||
| Accumulated other comprehensive loss | - | (1 | ) | |||
| Accumulated deficit | (448,767 | ) | (373,749 | ) | ||
| TOTAL SHAREHOLDERS’ EQUITY | 139,732 | 189,119 | ||||
| TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY | 162,165 | 210,002 | ||||
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS ( |
||||||||||||
| Twelve Months Ended |
Three Months Ended |
|||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||
| REVENUE | 13,021 | 11,283 | 3,719 | 3,000 | ||||||||
| COST OF REVENUE | 25,809 | 21,892 | 7,336 | 5,890 | ||||||||
| GROSS LOSS | (12,788 | ) | (10,609 | ) | (3,617 | ) | (2,890 | ) | ||||
| OPERATING EXPENSES: | ||||||||||||
| Research and development, net | 19,236 | 20,182 | 4,838 | 5,401 | ||||||||
| Sales and marketing | 5,665 | 3,410 | 1,999 | 889 | ||||||||
| General and administrative | 21,587 | 22,455 | 6,046 | 5,786 | ||||||||
| Change in contingent earnout liability | 7 | - | 7 | - | ||||||||
| Impairment of long-lived assets | 17,528 | - | 17,528 | - | ||||||||
| Other expenses, net | 1,423 | 90 | 1,383 | 9 | ||||||||
| TOTAL OPERATING EXPENSES | 65,446 | 46,137 | 31,801 | 12,085 | ||||||||
| OPERATING LOSS | (78,234 | ) | (56,746 | ) | (35,418 | ) | (14,975 | ) | ||||
| REALIZED INCOME (LOSS) FROM SALE OF MARKETABLE SECURITIES | - | 2 | - | |||||||||
| FINANCIAL INCOME, net | 1,424 | 2,870 | 351 | 820 | ||||||||
| OPERATING LOSS BEFORE INCOME TAXES | (76,810 | ) | (53,874 | ) | (35,067 | ) | (14,155 | ) | ||||
| INCOME TAX BENEFIT | 1,792 | 358 | 1,694 | 94 | ||||||||
| NET LOSS | (75,018 | ) | (53,516 | ) | (33,373 | ) | (14,061 | ) | ||||
| BASIC AND DILUTED LOSS PER SHARE | (1.16 | ) | (0.91 | ) | (0.50 | ) | (0.23 | ) | ||||
| Weighted average number of basic and diluted ordinary shares outstanding (in thousands) | 64,790 | 58,673 | 67,059 | 60,139 | ||||||||
| NET LOSS | (75,018 | ) | (53,516 | ) | (33,373 | ) | (14,061 | ) | ||||
| Other comprehensive income (loss): | ||||||||||||
| Reclassification of net losses (income) realized in income statement | - | (2 | ) | - | - | |||||||
| Unrealized gain (loss) from marketable securities | 1 | 306 | - | (13 | ) | |||||||
| Total other comprehensive income (loss): | 1 | 304 | - | (13 | ) | |||||||
| Total comprehensive loss | (75,017 | ) | (53,212 | ) | (33,373 | ) | (14,074 | ) | ||||
UNAUDITED CONDENSED STATEMENT OF CHANGES IN SHAREHOLDERS’ EQUITY ( |
|||||||||||||||
| Accumulated | |||||||||||||||
| Ordinary shares | Additional | other | |||||||||||||
| Number of | paid-in | comprehensive | Accumulated | ||||||||||||
| shares | Amount | capital | loss | deficit | Total | ||||||||||
| BALANCE AT |
57,778,628 | 165 | 515,887 | (305 | ) | (320,233 | ) | 195,514 | |||||||
| CHANGES DURING 2024: | |||||||||||||||
| Issuance of ordinary shares and warrants, net of issuance expenses ** | 5,046,990 | 14 | 37,820 | - | - | 37,834 | |||||||||
| Issuance of ordinary shares upon exercise of RSUs | 190,000 | * | - | - | - | ||||||||||
| Issuance of ordinary shares upon exercise of options | 746,383 | 2 | 1,668 | - | - | 1,670 | |||||||||
| Share-based compensation | - | - | 7,313 | - | - | 7,313 | |||||||||
| Unrealized gain from marketable securities, net | - | - | - | 304 | - | 304 | |||||||||
| Net loss for the year | - | - | - | - | (53,516 | ) | (53,516 | ) | |||||||
| BALANCE AT |
63,762,001 | 181 | 562,688 | (1 | ) | (373,749 | ) | 189,119 | |||||||
| CHANGES DURING 2025: | |||||||||||||||
| Issuance of ordinary shares, net of issuance expenses ** | 5,624,989 | 17 | 21,188 | - | - | 21,205 | |||||||||
| Issuance of ordinary shares upon exercise of RSUs | 12,985 | - | - | - | - | - | |||||||||
| Issuance of ordinary shares upon exercise of options | 74,027 | - | 163 | - | - | 163 | |||||||||
| Issuance of ordinary shares under settlement agreement with former stockholders of MDW | 116,226 | * | - | - | - | - | |||||||||
| Share-based compensation | - | - | 4,262 | - | - | 4,262 | |||||||||
| Unrealized gain from marketable securities, net | - | - | - | 1 | - | 1 | |||||||||
| Net loss for the year | - | - | - | - | (75,018 | ) | (75,018 | ) | |||||||
| BALANCE AT |
69,590,228 | 198 | 588,301 | - | (448,767 | ) | 139,732 | ||||||||
| * | Less than |
| ** | Issuance expenses totaled |
| Ordinary shares | Additional | Accumulated other |
||||||||||||
| Number of shares |
Amount | paid-in capital |
comprehensive loss |
Accumulated deficit |
Total | |||||||||
| BALANCE AT |
65,382,892 | 185 | 571,918 | - | (415,394 | ) | 156,709 | |||||||
| Changes during the period: | ||||||||||||||
| Issuance of ordinary shares, net of issuance expenses ** | 4,204,086 | 13 | 15,497 | - | - | 15,510 | ||||||||
| Issuance of ordinary shares upon exercise of RSUs | 3,250 | |||||||||||||
| Share-based compensation | - | - | 886 | - | - | 886 | ||||||||
| Net loss for the period | - | - | - | - | (33,373 | ) | (33,373 | ) | ||||||
| BALANCE AT |
69,590,228 | 198 | 588,301 | - | (448,767 | ) | 139,732 | |||||||
| Ordinary shares | Additional | Accumulated other |
|||||||||||||
| Number of shares |
Amount | paid-in capital |
comprehensive loss |
Accumulated deficit |
Total | ||||||||||
| BALANCE AT |
58,521,934 | 167 | 523,396 | 12 | (359,688 | ) | 163,887 | ||||||||
| Changes during the period: | |||||||||||||||
| Issuance of ordinary shares, net of issuance expenses ** | 5,046,990 | 14 | 37,820 | - | - | 37,834 | |||||||||
| Issuance of ordinary shares upon exercise of RSUs | 190,000 | * | - | - | - | - | |||||||||
| Issuance of ordinary shares upon exercise of options | 3,077 | * | 4 | - | - | 4 | |||||||||
| Share-based compensation | - | - | 1,468 | - | - | 1,468 | |||||||||
| Unrealized loss from marketable securities | - | - | - | (13 | ) | - | (13 | ) | |||||||
| Net loss for the period | - | - | - | - | (14,061 | ) | (14,061 | ) | |||||||
| BALANCE AT |
63,762,001 | 181 | 562,688 | (1 | ) | (373,749 | ) | 189,119 | |||||||
| * | Less than |
| ** | Issuance expenses totaled |
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS ( |
||||||
| Year ended |
||||||
| 2025 | 2024 | |||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||
| Net loss for the year | (75,018 | ) | (53,516 | ) | ||
| Adjustments required to reconcile net loss to net cash used in operating activities: | ||||||
| Share-based compensation | 4,190 | 7,261 | ||||
| Amortization of intangible assets | 10,508 | 10,612 | ||||
| Impairment of long-lived assets | 17,528 | - | ||||
| Change in contingent earnout liability | 7 | - | ||||
| Depreciation | 1,189 | 1,121 | ||||
| Deferred tax liability, net | (1,976 | ) | (377 | ) | ||
| Realized income from sale of marketable securities | - | (2 | ) | |||
| Exchange rate differentials | 153 | (512 | ) | |||
| Amortization of premium, discount and accrued interest on marketable securities | 108 | (260 | ) | |||
| Interest of short-term deposits | (459 | ) | - | |||
| Loss from disposal of property and equipment | 207 | 202 | ||||
| Changes in operating assets and liabilities, net of effects of businesses acquired: | ||||||
| Change in inventories | (325 | ) | (277 | ) | ||
| Accounts receivable, net | 107 | (321 | ) | |||
| Prepaid expenses and other current assets | 409 | 190 | ||||
| Other non-current assets | 29 | 218 | ||||
| Accounts payable | 288 | (1,316 | ) | |||
| Accrued expenses and other liabilities | 1,182 | 490 | ||||
| Operating lease assets and liabilities | 655 | 209 | ||||
| Deferred revenue | 130 | (403 | ) | |||
| Other long-term liabilities | 295 | 83 | ||||
| Net cash used in operating activities | (40,793 | ) | (36,598 | ) | ||
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||
| Release of restricted deposits | - | 46 | ||||
| Cash paid for business combinations | (200 | ) | - | |||
| Proceeds from maturity of marketable securities | 18,295 | 41,187 | ||||
| Purchase of marketable securities | - | (33,017 | ) | |||
| Investment in short-term deposits | - | (15,500 | ) | |||
| Maturity of short-term deposits | 15,500 | - | ||||
| Investment in long-term deposits | - | (10,000 | ) | |||
| Investment in SAFE | (15 | ) | - | |||
| Purchase of property and equipment | (4,207 | ) | (2,767 | ) | ||
| Net cash provided by (used in) investing activities | 29,373 | (20,051 | ) | |||
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||
| Proceeds from issuance of ordinary shares and warrants, net of issuance costs | 21,205 | 37,834 | ||||
| Proceeds from issuance of ordinary shares upon exercise of options | 163 | 1,670 | ||||
| Net cash provided by financing activities | 21,368 | 39,504 | ||||
| EFFECT OF CHANGES IN EXCHANGE RATES ON CASH AND CASH EQUIVALENTS | (101 | ) | 72 | |||
| NET CHANGE IN CASH AND CASH EQUIVALENTS | 9,847 | (17,073 | ) | |||
| CASH AND CASH EQUIVALENTS AT BEGINNING OF THE YEAR | 39,304 | 56,377 | ||||
| CASH AND CASH EQUIVALENTS AT END OF THE YEAR | 49,151 | 39,304 | ||||
| SUPPLEMENTARY INFORMATION ON ACTIVITIES INVOLVING CASH FLOWS: | ||||||
| Cash paid for income taxes | 184 | 53 | ||||
| Cash paid for interest | 132 | 140 | ||||
| SUPPLEMENTARY INFORMATION ON ACTIVITIES NOT INVOLVING CASH FLOWS: | ||||||
| Contingent earnout liability recognized in connection with a business combination | 470 | - | ||||
| Non-cash purchase of property and equipment | 74 | 223 | ||||
| Operating lease liabilities arising from obtaining operating right-of use assets | 131 | - | ||||
| The accompanying notes are an integral part of the unaudited condensed consolidated financial statements UNAUDITED RECONCILIATION OF GAAP AND NON-GAAP RESULTS ( |
Use of Non-GAAP Financial Measures
The unaudited condensed consolidated financial information is prepared in conformity with GAAP. The Company uses information about certain financial measures that are not prepared in accordance with GAAP, including non-GAAP net loss attributable to ordinary shares, non-GAAP cost of revenue, non-GAAP gross loss, non-GAAP gross loss margin, non-GAAP research and development expenses, net, non-GAAP sales and marketing expenses, non-GAAP general and administrative expenses, non-GAAP other expenses and non-GAAP basic and diluted loss per share. These non-GAAP measures are adjusted for (as applicable) amortization of intangible assets, share-based compensation expenses, change in contingent earnout liability, expenses related to an offering and legal fees, expenses in connection with the settlement with a shareholder and an Impairment of long-lived assets. The Company believes that separate analysis and exclusion of the one-off or non-cash impact of the above reconciling items (as applicable) adds clarity to the constituent parts of its performance. The Company reviews these non-GAAP financial measures together with GAAP financial measures to obtain a better understanding of its operating performance. It uses the non-GAAP financial measures for planning, forecasting, and measuring results against the forecast. The Company believes that the non-GAAP financial measures are useful supplemental information for investors and analysts to assess its operating performance. However, these non-GAAP measures are not measures of financial performance under GAAP and, accordingly, should not be considered as alternatives to GAAP measures as indicators of operating performance.
Reconciliation of GAAP net loss attributable to ordinary shares to non-GAAP net loss attributable to ordinary shares and non-GAAP basic and diluted loss per share (
| Twelve Months Ended | Three Months Ended | |||||||
| 2025 | 2024 | 2025 | 2024 | |||||
| GAAP net loss attributable to ordinary shares | 75,018 | 53,516 | 33,373 | 14,061 | ||||
| Non-GAAP adjustments: | ||||||||
| Less: Litigation expenses | 57 | 81 | 24 | 5 | ||||
| Less: Settlement with a shareholder | 1,260 | - | 1,260 | - | ||||
| Less: Amortization of intangible assets | 10,508 | 10,612 | 2,549 | 2,653 | ||||
| Less: Impairment of long-lived assets | 17,528 | - | 17,528 | - | ||||
| Less: Offering expenses | - | 420 | - | - | ||||
| Less: Change in the fair value of earn out liabilities’ obligation | 7 | - | 7 | - | ||||
| Less: Share-based compensation | 4,190 | 7,261 | 814 | 1,416 | ||||
| Non-GAAP net loss attributable to ordinary shares | 41,468 | 35,142 | 11,191 | 9,987 | ||||
| BASIC AND DILUTED LOSS PER SHARE | 0.64 | 0.60 | 0.17 | 0.17 | ||||
| WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES (in thousands) | 64,790 | 58,673 | 67,059 | 60,139 | ||||
Reconciliation of GAAP cost of revenue to non-GAAP cost of revenue (
| GAAP cost of revenue | 25,809 | 21,892 | 7,336 | 5,890 | ||||
| Non-GAAP adjustments: | ||||||||
| Amortization of intangible assets | 10,115 | 10,224 | 2,447 | 2,556 | ||||
| Share-based compensation | 125 | 227 | (18 | ) | 54 | |||
| Non-GAAP cost of revenue | 15,569 | 11,441 | 4,907 | 3,280 |
Reconciliation of GAAP gross loss to non-GAAP gross profit (
| GAAP gross loss | (12,788 | ) | (10,609 | ) | (3,617 | ) | (2,890 | ) | |||
| Non-GAAP adjustments: | |||||||||||
| Amortization of intangible assets | 10,115 | 10,224 | 2,447 | 2,556 | |||||||
| Share-based compensation | 125 | 227 | (18 | ) | 54 | ||||||
| Non-GAAP gross loss | (2,548 | ) | (158 | ) | (1,188 | ) | (280 | ) |
Reconciliation of GAAP gross loss margin to non-GAAP gross profit margin (in percentage of revenue)
| GAAP gross loss margin | (98 | )% | (94 | )% | (97 | )% | (96 | )% | |||
| Non-GAAP adjustments: | |||||||||||
| Amortization of intangible assets | 78 | % | 91 | % | 66 | % | 85 | % | |||
| Share-based compensation | 0 | % | 2 | % | (1 | )% | 2 | % | |||
| Non-GAAP gross loss margin | (20 | )% | (1 | )% | (32 | )% | (9 | )% |
Reconciliation of GAAP research and development, expenses, net, to non-GAAP research and development expenses, net (
| GAAP research and development expenses, net | 19,236 | 20,182 | 4,838 | 5,401 | |||
| Non-GAAP adjustments: | |||||||
| Share-based compensation | 1,182 | 2,448 | 167 | 409 | |||
| Non-GAAP research and development expenses, net | 18,054 | 17,734 | 4,671 | 4,992 |
Reconciliation of GAAP sales and marketing expenses to non-GAAP sales and marketing expenses (
| GAAP sales and marketing expenses | 5,665 | 3,410 | 1,999 | 889 | |||
| Non-GAAP adjustments: | |||||||
| Amortization of intangible assets | 393 | 388 | 102 | 97 | |||
| Share-based compensation | 355 | 717 | 92 | 147 | |||
| Non-GAAP sales and marketing expenses | 4,917 | 2,305 | 1,805 | 647 |
Reconciliation of GAAP general and administrative expenses to non-GAAP general and administrative expenses (
| GAAP general and administrative expenses | 21,587 | 22,455 | 6,046 | 5,786 | |||
| Non-GAAP adjustments: | |||||||
| Litigation expenses | 57 | 81 | 24 | 5 | |||
| Offering expenses | - | 420 | - | - | |||
| Share-based compensation | 2,528 | 3,869 | 573 | 808 | |||
| Non-GAAP general and administrative expenses | 19,002 | 18,085 | 5,449 | 4,973 |
Reconciliation of GAAP other expenses (income) to non-GAAP other expenses (
| GAAP other expenses | 1,423 | 90 | 1,383 | 9 | |||
| Non-GAAP adjustments: | |||||||
| Change in accrual in connection with the estimated settlement with a shareholder | 1,260 | - | 1,260 | - | |||
| Non-GAAP other expenses | 163 | 90 | 123 | 9 |
Investor Contact
mike.cavanaugh@icrhealthcare.com
Source: Nano-X Imaging Ltd